Prognostic Significance of P16 Expression and P53 Expression in Primary Vaginal Cancer

Chika R. Nwachukwu, Jeremy P. Harris, Alex Chin, Rie Von Eyben, Stephanie Giaretta, Jenny L. Shaffer, Susan M. Hiniker, Daniel S. Kapp, Ann K. Folkins, Elizabeth A. Kidd

Research output: Contribution to journalArticle

Abstract

To evaluate the correlation between p16 expression and clinical outcomes in patients with primary vaginal cancer treated with definitive radiotherapy. P16 immunohistochemical was performed on 25 patient samples and recorded from pathology reports in 7 patients. P53 immunohistochemical was performed on 3 p16-negative samples. Baseline characteristics were compared using the Fisher exact test. Outcomes were compared using log-rank tests, and cox proportional hazards models. Survival and recurrence analysis was performed with the Kaplan-Meier method and cumulative incidence estimates. P16 expression was positive in 29 patients and negative in 3 patients. Two of the p16-negative tumors showed positive expression of p53. The median overall survival, progression-free survival and 2-yr cumulative incidence of recurrence were 66 mo [95% confidence interval (CI), 31-96], 34 mo (95% CI, 21-86), and 19% (95% CI, 7%-34%), respectively. P16-positive tumors had higher median overall survival and progression-free survival compared with p16-negative tumors (82 vs. 31 mo, P=0.02 and 35 vs 16 mo, P=0.04, respectively). The 2-yr cumulative incidence of recurrence was 14% for p16-positive tumors compared with 67% for p16-negative tumors (P=0.07). On univariable analysis, p16-negative status, age older than 65, and advanced stage were associated with inferior overall survival. P16 negativity is an independent predictor of inferior overall survival. P16-positive vaginal cancers have a better prognosis and decreased incidence of recurrence compared with p16-negative tumors. These prognostic findings associated with p16-negative vaginal cancers will need to be confirmed in larger patient cohorts.

Original languageEnglish (US)
Pages (from-to)588-596
Number of pages9
JournalInternational Journal of Gynecological Pathology
Volume38
Issue number6
DOIs
StatePublished - Nov 1 2019
Externally publishedYes

Fingerprint

Vaginal Neoplasms
Recurrence
Neoplasms
Survival
Incidence
Confidence Intervals
Disease-Free Survival
Survival Analysis
Proportional Hazards Models
Radiotherapy
Pathology

Keywords

  • p16 IHC
  • P53 IHC staining
  • Vaginal cancer

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Obstetrics and Gynecology

Cite this

Prognostic Significance of P16 Expression and P53 Expression in Primary Vaginal Cancer. / Nwachukwu, Chika R.; Harris, Jeremy P.; Chin, Alex; Von Eyben, Rie; Giaretta, Stephanie; Shaffer, Jenny L.; Hiniker, Susan M.; Kapp, Daniel S.; Folkins, Ann K.; Kidd, Elizabeth A.

In: International Journal of Gynecological Pathology, Vol. 38, No. 6, 01.11.2019, p. 588-596.

Research output: Contribution to journalArticle

Nwachukwu, CR, Harris, JP, Chin, A, Von Eyben, R, Giaretta, S, Shaffer, JL, Hiniker, SM, Kapp, DS, Folkins, AK & Kidd, EA 2019, 'Prognostic Significance of P16 Expression and P53 Expression in Primary Vaginal Cancer', International Journal of Gynecological Pathology, vol. 38, no. 6, pp. 588-596. https://doi.org/10.1097/PGP.0000000000000568
Nwachukwu, Chika R. ; Harris, Jeremy P. ; Chin, Alex ; Von Eyben, Rie ; Giaretta, Stephanie ; Shaffer, Jenny L. ; Hiniker, Susan M. ; Kapp, Daniel S. ; Folkins, Ann K. ; Kidd, Elizabeth A. / Prognostic Significance of P16 Expression and P53 Expression in Primary Vaginal Cancer. In: International Journal of Gynecological Pathology. 2019 ; Vol. 38, No. 6. pp. 588-596.
@article{84dc0fc86de74c54a277248e7d2e6956,
title = "Prognostic Significance of P16 Expression and P53 Expression in Primary Vaginal Cancer",
abstract = "To evaluate the correlation between p16 expression and clinical outcomes in patients with primary vaginal cancer treated with definitive radiotherapy. P16 immunohistochemical was performed on 25 patient samples and recorded from pathology reports in 7 patients. P53 immunohistochemical was performed on 3 p16-negative samples. Baseline characteristics were compared using the Fisher exact test. Outcomes were compared using log-rank tests, and cox proportional hazards models. Survival and recurrence analysis was performed with the Kaplan-Meier method and cumulative incidence estimates. P16 expression was positive in 29 patients and negative in 3 patients. Two of the p16-negative tumors showed positive expression of p53. The median overall survival, progression-free survival and 2-yr cumulative incidence of recurrence were 66 mo [95{\%} confidence interval (CI), 31-96], 34 mo (95{\%} CI, 21-86), and 19{\%} (95{\%} CI, 7{\%}-34{\%}), respectively. P16-positive tumors had higher median overall survival and progression-free survival compared with p16-negative tumors (82 vs. 31 mo, P=0.02 and 35 vs 16 mo, P=0.04, respectively). The 2-yr cumulative incidence of recurrence was 14{\%} for p16-positive tumors compared with 67{\%} for p16-negative tumors (P=0.07). On univariable analysis, p16-negative status, age older than 65, and advanced stage were associated with inferior overall survival. P16 negativity is an independent predictor of inferior overall survival. P16-positive vaginal cancers have a better prognosis and decreased incidence of recurrence compared with p16-negative tumors. These prognostic findings associated with p16-negative vaginal cancers will need to be confirmed in larger patient cohorts.",
keywords = "p16 IHC, P53 IHC staining, Vaginal cancer",
author = "Nwachukwu, {Chika R.} and Harris, {Jeremy P.} and Alex Chin and {Von Eyben}, Rie and Stephanie Giaretta and Shaffer, {Jenny L.} and Hiniker, {Susan M.} and Kapp, {Daniel S.} and Folkins, {Ann K.} and Kidd, {Elizabeth A.}",
year = "2019",
month = "11",
day = "1",
doi = "10.1097/PGP.0000000000000568",
language = "English (US)",
volume = "38",
pages = "588--596",
journal = "International Journal of Gynecological Pathology",
issn = "0277-1691",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Prognostic Significance of P16 Expression and P53 Expression in Primary Vaginal Cancer

AU - Nwachukwu, Chika R.

AU - Harris, Jeremy P.

AU - Chin, Alex

AU - Von Eyben, Rie

AU - Giaretta, Stephanie

AU - Shaffer, Jenny L.

AU - Hiniker, Susan M.

AU - Kapp, Daniel S.

AU - Folkins, Ann K.

AU - Kidd, Elizabeth A.

PY - 2019/11/1

Y1 - 2019/11/1

N2 - To evaluate the correlation between p16 expression and clinical outcomes in patients with primary vaginal cancer treated with definitive radiotherapy. P16 immunohistochemical was performed on 25 patient samples and recorded from pathology reports in 7 patients. P53 immunohistochemical was performed on 3 p16-negative samples. Baseline characteristics were compared using the Fisher exact test. Outcomes were compared using log-rank tests, and cox proportional hazards models. Survival and recurrence analysis was performed with the Kaplan-Meier method and cumulative incidence estimates. P16 expression was positive in 29 patients and negative in 3 patients. Two of the p16-negative tumors showed positive expression of p53. The median overall survival, progression-free survival and 2-yr cumulative incidence of recurrence were 66 mo [95% confidence interval (CI), 31-96], 34 mo (95% CI, 21-86), and 19% (95% CI, 7%-34%), respectively. P16-positive tumors had higher median overall survival and progression-free survival compared with p16-negative tumors (82 vs. 31 mo, P=0.02 and 35 vs 16 mo, P=0.04, respectively). The 2-yr cumulative incidence of recurrence was 14% for p16-positive tumors compared with 67% for p16-negative tumors (P=0.07). On univariable analysis, p16-negative status, age older than 65, and advanced stage were associated with inferior overall survival. P16 negativity is an independent predictor of inferior overall survival. P16-positive vaginal cancers have a better prognosis and decreased incidence of recurrence compared with p16-negative tumors. These prognostic findings associated with p16-negative vaginal cancers will need to be confirmed in larger patient cohorts.

AB - To evaluate the correlation between p16 expression and clinical outcomes in patients with primary vaginal cancer treated with definitive radiotherapy. P16 immunohistochemical was performed on 25 patient samples and recorded from pathology reports in 7 patients. P53 immunohistochemical was performed on 3 p16-negative samples. Baseline characteristics were compared using the Fisher exact test. Outcomes were compared using log-rank tests, and cox proportional hazards models. Survival and recurrence analysis was performed with the Kaplan-Meier method and cumulative incidence estimates. P16 expression was positive in 29 patients and negative in 3 patients. Two of the p16-negative tumors showed positive expression of p53. The median overall survival, progression-free survival and 2-yr cumulative incidence of recurrence were 66 mo [95% confidence interval (CI), 31-96], 34 mo (95% CI, 21-86), and 19% (95% CI, 7%-34%), respectively. P16-positive tumors had higher median overall survival and progression-free survival compared with p16-negative tumors (82 vs. 31 mo, P=0.02 and 35 vs 16 mo, P=0.04, respectively). The 2-yr cumulative incidence of recurrence was 14% for p16-positive tumors compared with 67% for p16-negative tumors (P=0.07). On univariable analysis, p16-negative status, age older than 65, and advanced stage were associated with inferior overall survival. P16 negativity is an independent predictor of inferior overall survival. P16-positive vaginal cancers have a better prognosis and decreased incidence of recurrence compared with p16-negative tumors. These prognostic findings associated with p16-negative vaginal cancers will need to be confirmed in larger patient cohorts.

KW - p16 IHC

KW - P53 IHC staining

KW - Vaginal cancer

UR - http://www.scopus.com/inward/record.url?scp=85058190033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058190033&partnerID=8YFLogxK

U2 - 10.1097/PGP.0000000000000568

DO - 10.1097/PGP.0000000000000568

M3 - Article

C2 - 31593028

AN - SCOPUS:85058190033

VL - 38

SP - 588

EP - 596

JO - International Journal of Gynecological Pathology

JF - International Journal of Gynecological Pathology

SN - 0277-1691

IS - 6

ER -